Keyword search
Filter results by
Search HelpKeyword(s)
Subject
Survey or statistical program
Results
All (7)
All (7) ((7 results))
- 1. Results of the pilot survey on nanotechnologies ArchivedArticles and reports: 88-003-X200700210323Geography: CanadaDescription:
Although nanotechnology can be thought of as a sector of its own, it is clear that nanotechnology is a cross-sector phenomenon with potentially significant impacts. Nanotechnologies can be found in areas as diverse as biotechnology and health, agriculture, electronics and computer technology, environment and energy, optics, and in materials and manufacturing.
Release date: 2007-10-09 - Articles and reports: 88-003-X200700210326Geography: CanadaDescription:
Although private investors and government funding agencies have learned that the biotechnology sector requires a funding model different from that of traditional manufacturing, there is a paucity of empirical research investigating the links between characteristics of the funding model and firm performance. The purpose of this article is to examine which funding sources have the greatest influence on firm growth.
Release date: 2007-10-09 - Articles and reports: 88F0006X2005010Description:
This paper looks into Canadian innovative biotechnology firms' access to financing capital. Results show that over 70% of biotech firms that attempted to raise financing capital were successful. Funds were primarily sought for R&D activities and came primarily from Canadian venture capitalists. Harsher market conditions were the main reasons put forward by investors to limit or reject biotechnology firms' funding requests.
Release date: 2005-04-29 - Articles and reports: 88F0006X2005009Description:
The main indicators of biotechnology activities in Canada are presented in this article. The data are from the 2003 Biotechnology Use and Development Survey. Within the last few years, except for the number of employees with biotechnology-related responsibilities that remained stable, an increase in all the indicators was noticed. For example, the number of innovative firms involved in biotechnology activities rose from 375 in 2001 to 490 in 2003 and biotechnology revenues rose from $3.6 billion to $3.8 billion between 2001 and 2003. Also, biotechnology R&D spending increased by 11% between 2001 and 2003 and the amount of capital raised for biotechnology was up 73% during this period.
Release date: 2005-04-27 - Articles and reports: 88-003-X20030026570Geography: CanadaDescription:
In 2001, Canadian biotech firms raised $980 million in financing capital, a sharp drop from the $2.1 billion raised in 1999. Overall, 114 firms out of 188 (61%) that attempted to raise capital either failed or did not reach their targets. Why are biotech firms encountering difficulties in raising financing capital?
Release date: 2003-06-27 - Articles and reports: 88-003-X20030016468Geography: CanadaDescription:
New small firms with more long-term debt in their balance sheets tend to devote a smaller percentage of their investment expenditure to research and development. A recent Statistics Canada study on financing innovation in new small firms provides insight into an important segment of the small-firm population, namely successful entrants.
Release date: 2003-02-18 - Articles and reports: 11F0019M2002190Geography: CanadaDescription:
This paper investigates the financial characteristics of new small firms. The analysis develops a representative, small-firm financial profile and evaluates the extent to which the proportionate use of different instruments and sources is correlated with industry-level and firm-specific characteristics. Multivariate methods are then used to examine relationships among financial structure, R&D intensity, and innovation.
Our results suggest that relationships between knowledge intensity and capital structure are bidirectional. After a range of industry- and firm-level covariates are controlled for, firms that devote a higher percentage of their investment expenditure to R&D also exhibit fewer debt-intensive structures. Conversely, debt-intensive structures also act to constrain investments in R&D. These relationships, however, depend upon the type of debt in the asset mix. It is the share of long-term debt to total assets that is negatively related to investments in knowledge.
Release date: 2002-05-24
Data (0)
Data (0) (0 results)
No content available at this time.
Analysis (7)
Analysis (7) ((7 results))
- 1. Results of the pilot survey on nanotechnologies ArchivedArticles and reports: 88-003-X200700210323Geography: CanadaDescription:
Although nanotechnology can be thought of as a sector of its own, it is clear that nanotechnology is a cross-sector phenomenon with potentially significant impacts. Nanotechnologies can be found in areas as diverse as biotechnology and health, agriculture, electronics and computer technology, environment and energy, optics, and in materials and manufacturing.
Release date: 2007-10-09 - Articles and reports: 88-003-X200700210326Geography: CanadaDescription:
Although private investors and government funding agencies have learned that the biotechnology sector requires a funding model different from that of traditional manufacturing, there is a paucity of empirical research investigating the links between characteristics of the funding model and firm performance. The purpose of this article is to examine which funding sources have the greatest influence on firm growth.
Release date: 2007-10-09 - Articles and reports: 88F0006X2005010Description:
This paper looks into Canadian innovative biotechnology firms' access to financing capital. Results show that over 70% of biotech firms that attempted to raise financing capital were successful. Funds were primarily sought for R&D activities and came primarily from Canadian venture capitalists. Harsher market conditions were the main reasons put forward by investors to limit or reject biotechnology firms' funding requests.
Release date: 2005-04-29 - Articles and reports: 88F0006X2005009Description:
The main indicators of biotechnology activities in Canada are presented in this article. The data are from the 2003 Biotechnology Use and Development Survey. Within the last few years, except for the number of employees with biotechnology-related responsibilities that remained stable, an increase in all the indicators was noticed. For example, the number of innovative firms involved in biotechnology activities rose from 375 in 2001 to 490 in 2003 and biotechnology revenues rose from $3.6 billion to $3.8 billion between 2001 and 2003. Also, biotechnology R&D spending increased by 11% between 2001 and 2003 and the amount of capital raised for biotechnology was up 73% during this period.
Release date: 2005-04-27 - Articles and reports: 88-003-X20030026570Geography: CanadaDescription:
In 2001, Canadian biotech firms raised $980 million in financing capital, a sharp drop from the $2.1 billion raised in 1999. Overall, 114 firms out of 188 (61%) that attempted to raise capital either failed or did not reach their targets. Why are biotech firms encountering difficulties in raising financing capital?
Release date: 2003-06-27 - Articles and reports: 88-003-X20030016468Geography: CanadaDescription:
New small firms with more long-term debt in their balance sheets tend to devote a smaller percentage of their investment expenditure to research and development. A recent Statistics Canada study on financing innovation in new small firms provides insight into an important segment of the small-firm population, namely successful entrants.
Release date: 2003-02-18 - Articles and reports: 11F0019M2002190Geography: CanadaDescription:
This paper investigates the financial characteristics of new small firms. The analysis develops a representative, small-firm financial profile and evaluates the extent to which the proportionate use of different instruments and sources is correlated with industry-level and firm-specific characteristics. Multivariate methods are then used to examine relationships among financial structure, R&D intensity, and innovation.
Our results suggest that relationships between knowledge intensity and capital structure are bidirectional. After a range of industry- and firm-level covariates are controlled for, firms that devote a higher percentage of their investment expenditure to R&D also exhibit fewer debt-intensive structures. Conversely, debt-intensive structures also act to constrain investments in R&D. These relationships, however, depend upon the type of debt in the asset mix. It is the share of long-term debt to total assets that is negatively related to investments in knowledge.
Release date: 2002-05-24
Reference (0)
Reference (0) (0 results)
No content available at this time.
- Date modified: